Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashima Salwan

Internal Medicine Elgin, IL Medical Doctor

NPI 1871785923 CMS profile 266737

2371 Bowes Rd Ste 100, Elgin, IL 60123

Open in the dashboard

General payments

$6,697

267 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashima Salwan of Elgin, IL is reported in the CMS Open Payments database as having received $6,697 across 267 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,204 53
2024 General $963 50
2023 General $2,372 39
2022 General $738 39
2021 General $515 33
2020 General $659 38
2019 General $246 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashima Salwan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ashima Salwan were reported at $1,204. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ashima Salwan Internal Medicine median Middle half National median
2019 $246 $159 $48–$570 $163
2020 $659 $119 $33–$402 $114
2021 $515 $135 $37–$521 $132
2022 $738 $141 $42–$496 $149
2023 $2,372 $149 $45–$519 $160
2024 $963 $154 $47–$537 $164
2025 $1,204 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,378 38 payments
  2. Lilly USA, LLC $719 39 payments
  3. Amgen Inc. $479 27 payments
  4. Astellas Pharma US Inc $464 17 payments
  5. AstraZeneca Pharmaceuticals LP $380 24 payments
  6. Amarin Pharma Inc. $362 15 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $253 15 payments
  8. Sumitomo Pharma America, Inc. $233 11 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $175 8 payments
  10. Abbott Laboratories $134 8 payments
  11. Other $1,120 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,708 261 payments
  2. Consulting Fee $1,740 2 payments
  3. Education $249 4 payments
Products named General payments · program years 2019–2025
  1. Otezla $348 20 payments
  2. Ozempic $327 17 payments
  3. JARDIANCE $323 18 payments
  4. MOUNJARO $310 16 payments
  5. Repatha $293 17 payments
  6. RYBELSUS $274 15 payments
  7. Vascepa $264 10 payments
  8. GEMTESA $233 11 payments
  9. ZEPBOUND $183 9 payments
  10. Kerendia $175 8 payments
  11. Other $3,138 189 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

2,224

Median for Internal Medicine: 777

Drug cost

$358,931

Median for Internal Medicine: $73,373

Branded share of claims

29.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 105 $154,186
Jardiance Empagliflozin Brand 60 $68,142
Mounjaro Tirzepatide Brand 37 $44,888
Myrbetriq Mirabegron Brand 25 $26,925
Januvia Sitagliptin Phosphate Brand 11 $18,631
Eliquis Apixaban Brand 39 $12,799
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $7,747
Vascepa Icosapent Ethyl Brand 29 $6,423
Atorvastatin Calcium Generic 228 $2,011
Albuterol Sulfate Hfa Albuterol Sulfate Brand 52 $1,307

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$61,863

Of which drugs: $9,000

Medicare patients

107

Average age 74

Services billed

908

73 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 47%
Arthritis 43%
Chronic kidney disease 26%
Depression 25%
Atrial fibrillation 23%
Osteoporosis 22%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 21 21 $6,134
Vaccine for influenza for injection into muscle 90662 Office 30 33 $2,670

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $90
  • Boehringer Ingelheim Pharmaceuticals, Inc. $54
$144 60 —
GEMTESA
  • Sumitomo Pharma America, Inc. $103
$103 — —
MOUNJARO
  • Lilly USA, LLC $92
$92 37 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —
ZEPBOUND
  • Lilly USA, LLC $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record